AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00842907
Drug: oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 20.0 mg capsule, once a day, every other day, during 24 weeks
Trial: NCT03467373
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
Trial: NCT00842907
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
Trial: NCT00682097
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses
Trial: NCT04330677
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
Trial: NCT04330677
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
Trial: NCT00535288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
Trial: NCT01007630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
Trial: NCT04615455
Drug: Cryostor CS10
RxNorm normalized name: CRYOSTOR CS5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CryoStor® CS10 freeze medium
Trial: NCT00745849
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00970775
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, single dose
Trial: NCT00970775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution,single dose
Trial: NCT04013243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
Trial: NCT03188172
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT04180384
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate
Trial: NCT00576680
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally once a day
Trial: NCT02661178
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01126359
Drug: Placebo-Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
Trial: NCT01010139
Drug: Codeine Sulfate
RxNorm normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg, 30 mg and 60 mg Tablet
Trial: NCT02177487
Drug: Telmisartan/hydrochlorothiazide
RxNorm normalized name: telmisartan/hydrochlorothiazide 80 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01916759
Drug: Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
Trial: NCT02632903
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00301873
Drug: IV Zometa
RxNorm normalized name: zoledronic acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
Trial: NCT02662556
Drug: sufentanil sublingual tablet 30 mcg
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
Trial: NCT02242331
Drug: Micardis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03970252
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03970252
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03014882
Drug: L-Carnitine and N-acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00775203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02679963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01203644
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of SKY0402 administered locally into the surgical wound.
Trial: NCT01732666
Drug: low dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
Trial: NCT04049448
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
Trial: NCT01860729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02724579
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01609127
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
Trial: NCT00864916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo three times per day for 48 weeks.
Trial: NCT00992589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules once daily in the morning.
Trial: NCT02827656
Drug: hCG luteal support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: luteal support as described and vaginal progesterone 200 mg 3 times a day
Trial: NCT01849887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03355482
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM saline injection at baseline
Trial: NCT03996369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
Trial: NCT00609063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken daily for 6 months
Trial: NCT01432600
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Trial: NCT03799094
Drug: Tyrosine kinase inhibitor
RxNorm normalized name: Protein-tyrosine kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
Trial: NCT01453582
Drug: Total Flavonoids of Propolis dropping pill
RxNorm normalized name: propolis Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
Trial: NCT01453582
Drug: total Flavonoids of Propolis dropping pill
RxNorm normalized name: propolis Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
Trial: NCT01150409
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
Trial: NCT01214057
Drug: Propofol and Remifentanyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
Trial: NCT01214057
Drug: Sevoflurane and Remifentanyl
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
Trial: NCT00088556
Drug: TLK286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
Trial: NCT00595374
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02543229
Drug: OPT-302
RxNorm normalized name: Glau-Opt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT-302 will be administered by intravitreal injection once every month for 3 months
Trial: NCT02543229
Drug: Lucentis™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
Trial: NCT00255424
Drug: ferumoxytol or oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01856686
Drug: BP22042013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
Trial: NCT02107963
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1800mg/m2/d X 2 days as a lymphodepleting regimen
Trial: NCT04300920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo tablet three times daily for 24 months.
Trial: NCT03020030
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care
Trial: NCT00468312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sprays in each nostril in the morning
Trial: NCT01937104
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%
Trial: NCT03020030
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT03020030
Drug: HYDROCORTISONE
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard of Care
Trial: NCT03020030
Drug: LEUCOVORIN CALCIUM
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care
Trial: NCT03020030
Drug: MERCAPTOPURINE
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT03020030
Drug: METHOTREXATE
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care
Trial: NCT02795949
Drug: De-escalation(short-spectrum antibiotic)
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for infusion
Trial: NCT01029405
Drug: AN2728
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment B, 2% or 0.5% applied once or twice daily
Trial: NCT01029405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment B Vehicle applied once or twice daily
Trial: NCT05592873
Drug: Neoadjuvant chemoradiotherapy (CRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with histological diagnosis of locally advanced rectal adenocarcinoma \[clinical T3-T4N0M0 or T(any)N+M0\] were treated with neoadjuvant CRT followed by curative intent elective surgery between January 2014 and December 2019.
Trial: NCT00409175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
Trial: NCT00430183
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intramuscularly
Trial: NCT00703703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily
Trial: NCT03986073
Drug: TQ-F3083 blank analog capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
Trial: NCT03986073
Drug: TQ-F3083 blank analog capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
Trial: NCT01845987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
Trial: NCT01264575
Drug: intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 11 mg with epinephrine 100 mcg
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 11 mg with epinephrine 100 mcg
Trial: NCT01264575
Drug: intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
Trial: NCT01277406
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration
Trial: NCT01264575
Drug: intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
Trial: NCT01264575
Drug: intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
Trial: NCT04793932
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
Trial: NCT04793932
Drug: short-course chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: other two months of chemotherapy after surgery
Trial: NCT04793932
Drug: long-course chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: other two months of chemotherapy before surgery
Trial: NCT03339297
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to local institutional guidelines, physician preference, and patient need.
Trial: NCT03203005
Drug: IMA970A plus CV8102 and Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms \[µg\] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months.
Trial: NCT00504127
Drug: Naproxen 500 mg bid
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg bid
Trial: NCT00504127
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00603772
Drug: Atralin (tretinoin) gel, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
Trial: NCT03726996
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug (desipramine) provided in tablet form to be taken daily.
Trial: NCT01535976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo~.9 normal saline infusion
Trial: NCT02012582
Drug: VAS203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion
Trial: NCT03967691
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml NaCl 0.9% will be infused over 1 hour
Trial: NCT01147133
Drug: Kardogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x75 mg